• FEBRUARY 12, 2002

Wockhardt: Impressive performance

Wockhardt Ltd has declared encouraging results for FY02. While sales have grown by more than 16%, net profit forged ahead by 43% to more than a Rs 1 bn. This was mainly on the back of an impressive 300 basis points rise in operating margins. However, interest cost shot up considerably to Rs 38 m. On a consolidated basis, sales for the quarter grew by 14% to Rs 2 bn while profits grew by 37%.

(Rs m)4QFY014QFY02ChangeFY01FY02Change
Net sales 1,492 1,779 19.2% 5,585 6,494 16.3%
Other Income - 5 - 53 36 -32.1%
Expenditure 1,236 1,384 12.0% 4,636 5,178 11.7%
Operating Profit (EBDIT) 256 395 54.3% 949 1,316 38.7%
Operating Profit Margin (%)17.2%22.2% 17.0%20.3% 
Interest 4 28 - 135 144 6.7%
Depreciation 24 35 45.8% 97 122 25.8%
Profit before Tax 228 337 47.8% 770 1,086 41.0%
Other Adjustments - -   - -  
Tax 19 12 -36.8% 54 64 18.5%
Profit after Tax/(Loss) 209 325 55.5% 716 1,022 42.7%
Net profit margin (%)14.0%18.3% 12.8%15.7% 
No. of Shares (eoy) (m) 36.3 36.3   36.3 36.3  
Diluted Earnings per share 23.0 35.8   19.7 28.2  
P/E (at current price) 13.6  17.3 

The growth was mainly driven by aggressive new product launches in the domestic market and increasing penetration on the exports front. The company's exports grew by 41% during the year to Rs 2 bn. This was driven by over 85% growth in value-added formulations, accounting for almost a third of Wockhardt’s exports. Wockhardt's international business (including Wallis) now constitutes 35% of the total turnover and is growing rapidly. During the year, Wockhardt significantly expanded the manufacturing capacities of its bulk-actives 'Dextropropoxyphene' and Vitamin B12. These would enable Wockhardt to maintain the current growth rates by capturing a larger slice in the global market.

Two biotech products of the company viz. 'Biovac' (Hepatitis B vaccine) and 'Epox' (Erythopoetin) grew by more than 100% during the year. Biotech business now accounts for almost 10% of the company's turnover.

(Rs m)4QFY014QFY02*ChangeFY01FY02*Change
Formulations- Branded 921 1,008 9.4% 3,556 3,973 11.7%
Formulations- Generics 93 75 -19.4% 471 375 -20.4%
Exports 382 589 54.2% 1,212 1,712 41.3%
Bulk Drugs- Domestic 93 107 15.1% 346 433 25.1%
TOTAL 1,489 1,779 19.5% 5,585 6,493 16.3%
*period ending December'01

The rise in operating margins and performance of the key products of the company are impressive. At the current market price of Rs 486, the stock trades at a P/E multiple of 17x FY02 earnings. The stock seems to be fairly valued when compared to its peer companies like Dr. Reddy's and Ranbaxy.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407